CompletedNCT02804568
ALKS 3831 Safety and Drug Levels in Schizophrenia
About this title
Read the official source — NCT02804568This study evaluated the safety of ALKS 3831 for people with schizophrenia.
Medication studyAges 18–55United States
Understand this study
What did researchers investigate?
This study evaluated the safety of ALKS 3831 for people with schizophrenia.
Who was this study for?
This study was for people with schizophrenia. Listed age limits: 18 years to 55 years. Other eligibility criteria applied.
- Listed locations
- Little Rock and 2 more locationsSee all locations and recruitment
- Study phase
- Phase 1Usually an early study focused on safety, tolerability, dosage, and side effects.
Study information
Study start dateJune 2016
- Recruitment status
- Completed
- Enrollment listed in the registry
- 42
- Sponsor
- Alkermes, Inc.
- Sponsor type
- Other organization
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 1Usually an early study focused on safety, tolerability, dosage, and side effects.
- Locations
- United States
- Age range
- From 18 Years to 55 Years
- Official registry ID
- NCT02804568
- Official title
Show the full official title
A Multiple-dose, Open-label Study to Evaluate the Pharmacokinetics, Safety and Tolerability of ALKS 3831 in Adult Subjects With Schizophrenia
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Little Rock · Clementon · Dayton
Interested in joining this study?
Questions about this study
What did researchers investigate?
This study evaluated the safety of ALKS 3831 for people with schizophrenia.
Who is behind this study?
The study sponsor is Alkermes, Inc.
Did this study involve medication?
Yes. The study involved medication, including ALKS 3831.
Who was this study for?
This study was for people with schizophrenia. Listed age limits: 18 years to 55 years. Other eligibility criteria applied.
